Long-term hormone therapy – the latest review from Cochrane

Tagged :
Text Size: Normal / Medium / Large
Printer-friendly versionPrinter-friendly version

The latest Cochrane review on the evidence on hormonal therapy (HT) in peri- and postmenopausal women finds:

“HT significantly increases the risk of a coronary event, venous thrombo-embolism, stroke, breast cancer, gallbladder disease and death from lung cancer. Oestrogen-only HT has many of the same risks apart from risk of breast cancer. The only significant benefit found was a decrease in risk of fractures after long-term use for women with osteoporosis. It is generally recommended that HT only be used as management for osteoporosis in women at significant risk.”

Read the whole review.